MorphoSys and I-Mab Biopharma Announce First Patient Dosed in Phase 3 Clinical Study of MOR202/TJ202 in Multiple Myeloma
PLANEGG/MUNICH, GERMANY and SHANGHAI, CHINA / ACCESSWIRE / April 29, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX...